Arterial thrombosis in four patients treated with thalidomide.
Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature. Seven arterial thrombotic events have been reported in patients receiving thalidomide with 3 cases occurring in patients with other predisposing conditions. We report 4 additional cases of arterial thromboses in 1 lymphoma and 3 myeloma patients treated with thalidomide. The mechanism for these events is unclear; however, it is significant that 2 patients were receiving concomitant anticoagulation with aspirin and warfarin.
Scarpace
Sarah L
SL
Albany College of Pharmacy, NY 12208, USA.
Hahn
Theresa
T
Roy
Hilary
H
Brown
Karen
K
Paplham
Pamela
P
Chanan-Khan
Asher
A
van Besien
Koen
K
McCarthy
Philip L
PL
D000368:Aged; D001157:Arterial Occlusive Diseases; D001241:Aspirin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D020767:Intracranial Thrombosis / Q000139:chemically induced; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced*; D014859:Warfarin / Q000627:therapeutic use
D013792:Thalidomide; D014859:Warfarin; D001241:Aspirin